Trodelvy (sacituzumab govitecan) successful in Phase III ASCENT breast cancer study

Sacituzumab govitecan, an antibody-drug conjugate, showed a statistically significant improvement in progression free survival (PFS) compared to chemotherapy. Median PFS for patients who received the drug was 5.6 months, compared to 1.7 months for those who underwent chemotherapy

SPS commentary:

Sacituzumab govitecan is licensed for this indication in the US, and undergoing investigation in Phase 3 clinical trials for this indication in the EU.


Biospace Inc.